Pharmacological management of Idiopathic Pulmonary Fibrosis: current and emerging options

Introduction Idiopathic Pulmonary Fibrosis is a chronic, progressive lung disease characterized by worsening lung scarring and the radiological/histological pattern of usual interstitial pneumonia. Substantial progress has been made in the clinical management of IPF in the last decade. The two novel antifibrotics, Nintedanib and Pirfenidone have changed the landscape of IPF, by hindering disease progression; however, the drugs have significant discontinuation rates, due to adverse events and do not offer a definitive cure, as such IPF remains a deleterious disease with poor survival. Areas covered In this review, the authors focus on the current and emerging pharmacological options in the treatment of IPF. They include a summary of the current approach including treatment of comorbidities and then discuss promising drugs in the drug pipeline. Expert opinion IPF remains a disease with detrimental outcomes. The plethora of emerging pharmacological treatments brings hope for the future. The current pharmacological 'one fits all' approach has been proven effective in slowing disease progression. The future lies in an oncological approach with combination of therapies. We expect to see a change in clinical trial endpoints and a more inclusive approach for the diagnosis of IPF.

Automated summary

Idiopathic Pulmonary Fibrosis (IPF) is a chronic lung disease characterized by worsening lung scarring. Although novel antifibrotics Nintedanib and Pirfenidone have changed the landscape of IPF, they have significant discontinuation rates and do not offer a definitive cure. Emerging pharmacological treatments bring hope for the future of IPF, with a potential shift towards an oncological approach and more inclusive diagnostic methods expected.